Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Cash & Current Investments (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Cash & Current Investments for 14 consecutive years, with $7.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Current Investments fell 40.6% year-over-year to $7.8 million, compared with a TTM value of $7.8 million through Sep 2025, down 40.6%, and an annual FY2024 reading of $10.7 million, down 3.01% over the prior year.
  • Cash & Current Investments was $7.8 million for Q3 2025 at BioRestorative Therapies, down from $11.7 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $30.5 million in Q1 2024 and bottomed at $1.1 million in Q3 2021.
  • Average Cash & Current Investments over 5 years is $14.1 million, with a median of $13.9 million recorded in 2024.
  • The sharpest move saw Cash & Current Investments skyrocketed 52220.27% in 2021, then crashed 70.14% in 2025.
  • Year by year, Cash & Current Investments stood at $21.0 million in 2021, then dropped by 29.85% to $14.7 million in 2022, then fell by 24.97% to $11.1 million in 2023, then fell by 3.01% to $10.7 million in 2024, then decreased by 27.56% to $7.8 million in 2025.
  • Business Quant data shows Cash & Current Investments for BRTX at $7.8 million in Q3 2025, $11.7 million in Q2 2025, and $9.1 million in Q1 2025.